Period Pills for Menstrual Regulation: A New Reproductive Health Option
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Mifepristone + Misoprostol.
- Who it may be relevant to
- Registry conditions: Menstrual Regulation, Menstrual Health Intervention. Basic parameters: from 18 years · Female.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- United States
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
The Period Pills Study is a prospective observational study among people who decide to use a combination of mifepristone and misoprostol for menstrual regulation.
Detailed description
Period pills (a combination of mifepristone and misoprostol) for people who suspect, but have not confirmed pregnancy, has the potential to fulfill this growing need. In the United States (U.S.), a handful of providers currently offer period pills alongside other contraceptive and abortion services in their practice (https://www.periodpills.org/providers). This proposed study would aim to assess the acceptability of this growing service as a fertility regulation method to be utilized before a person confirms they are pregnant.
Dr. Ushma Upadhyay (Professor) and Dr. Tania Serna (Associate Clinical Professor) at UCSF's Department of Obstetrics, Gynecology \& Reproductive Science are proposing the Period Pills Study to test a traditional but underutilized framework of menstrual regulation for pregnancy loss, to "bring back" a period when it is late, or missed. This study will aim to recruit 100 participants who have a late period to address research questions that focus on the feasibility and acceptability of using period pills for menstrual regulation.
Interventions
- Drug Mifepristone + Misoprostol
Study participants are given mifepristone and misoprostol for menstrual regulation.
Primary outcome measures
- Interest in period pills [Time frame: Documented at Enrollment Survey]
- Satisfaction with period pills [Time frame: Documented at Follow-up Survey, 4 weeks after drug administration]
Secondary outcome measures (1)
- Efficacy of period pills [Time frame: Documented at the follow-up visit, through study completion at around 4 weeks after drug administration.]
Eligibility criteria
Inclusion criteria
- Be 18 years old or older
- Read and speak English
- Know the date of their last menstrual period within 2 days
- Have a period that is late by up to 21 days
- Must have had regular periods in the last 4 months
- Does not want to be pregnant
- Does not want to verify pregnancy status
- Understand that if they are pregnant, the pills will end their pregnancy
- Does not have contraindications to mifepristone and misoprostol (Risk factors for ectopic pregnancy; history of bleeding disorder or anticoagulant therapy; history of chronic adrenal failure, long-term corticosteroid therapy; allergy to mifepristone/misoprostol/prostaglandins; history of hemorrhagic disorders or anticoagulant therapy; history of inherited porphyrias; has an IUD; currently use a contraceptive implant or injectable)
Exclusion criteria
- Under 18 years old
- Does not read and speak English
- Does not know the date of their last menstrual period within 2 days
- Has not had regular periods in the last 4 months
- Wants to be pregnant
- Wants to verify pregnancy status
- Does not display understanding that if they are pregnant, the pills will end their pregnancy
- Has any contraindications to mifepristone and misoprostol (Risk factors for ectopic pregnancy; history of bleeding disorder or anticoagulant therapy; history of chronic adrenal failure, long-term corticosteroid therapy; allergy to mifepristone/misoprostol/prostaglandins; history of hemorrhagic disorders or anticoagulant therapy; history of inherited porphyrias; has an IUD; currently use a contraceptive implant or injectable)
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: Yes
Study design
- Allocation
- N/A
- Model
- Single group
- Masking
- Open label
- Primary purpose
- Other
Study locations
United States · 2 centers
- UCSF Advancing New Standards in Reproductive Health (ANSIRH) — Oakland
- Roanoke Health Center — Roanoke
Identifiers
NCT: NCT07671989 · 25-45282